KLS 3021
Alternative Names: KLS-3021Latest Information Update: 07 Jun 2022
At a glance
- Originator Kolon Life Science
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Gene transference; Immunologic cytotoxicity; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours